<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05040880</url>
  </required_header>
  <id_info>
    <org_study_id>IN_TMP_101</org_study_id>
    <nct_id>NCT05040880</nct_id>
  </id_info>
  <brief_title>A Bioequivalence Study Between Telmione Plus 80/12.5mg and Micardis Plus 80/12.5 mg in Healthy Adult Volunteers</brief_title>
  <official_title>A Bioequivalence Study to Compare and Evaluate the Pharmacokinetic Characteristics and the Safety After Administration of TELMIONE PLUS TAB. 80/12.5mg and MICARDIS PLUS TAB. 80/12.5mg in Healthy Adult Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>HK inno.N Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>HK inno.N Corporation</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the pharmacokinetics and safety after a single dose administration of Telmione&#xD;
      plus® 80/12.5mg and Micardis plus® 80/12.5mg in healthy adult volunteers&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 8, 2021</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax of telmisartan</measure>
    <time_frame>Up to 72 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUClast of telmisartan</measure>
    <time_frame>Up to 72 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of hydrochlorothiazide</measure>
    <time_frame>Up to 72 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUClast of hydrochlorothiazide</measure>
    <time_frame>Up to 72 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tmax of telmisartan</measure>
    <time_frame>Up to 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCinf of telmisartan</measure>
    <time_frame>Up to 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 of telmisartan</measure>
    <time_frame>Up to 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F of telmisartan</measure>
    <time_frame>Up to 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vd/F of telmisartan</measure>
    <time_frame>Up to 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of hydrochlorothiazide</measure>
    <time_frame>Up to 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCinf of hydrochlorothiazide</measure>
    <time_frame>Up to 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 of hydrochlorothiazide</measure>
    <time_frame>Up to 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F of hydrochlorothiazide</measure>
    <time_frame>Up to 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vd/F of hydrochlorothiazide</measure>
    <time_frame>Up to 72 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">46</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Sequence A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TRTR</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RTRT</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telmione plus 80/12.5mg</intervention_name>
    <description>Test drug (Fixed-dose combination drug of telmisartan 80mg and hydrochlorothiazide 12.5mg)</description>
    <arm_group_label>Sequence A</arm_group_label>
    <arm_group_label>Sequence B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Micardis plus 80/12.5mg</intervention_name>
    <description>Reference drug (Fixed-dose combination drug of telmisartan 80mg and hydrochlorothiazide 12.5mg)</description>
    <arm_group_label>Sequence A</arm_group_label>
    <arm_group_label>Sequence B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy adult volunteers aged ≥ 19 years at screening&#xD;
&#xD;
          -  Body weight ≥ 50kg and Body mass index (BMI) in the range of 18.0 and 30.0 kg/㎡&#xD;
&#xD;
          -  Subjects who do not have congenital or chronic diseases requiring treatment and have&#xD;
             no pathological symptoms or findings as a result of physical examination&#xD;
&#xD;
          -  Determined by the investigator to be eligible for study participation based on the&#xD;
             results of screening tests (clinical laboratory tests, vital signs, physical&#xD;
             examination, 12-lead ECG) conducted according to the IP characteristics&#xD;
&#xD;
          -  Subjects who decided to participate in the study and signed informed consent form&#xD;
             voluntarily after receiving detailed explanation of the study and fully understanding&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with a presence and a history of clinically significant hepatic, renal,&#xD;
             neurology, psychiatric, pulmonary, endocrine, hematologic, oncologic, genitourinary,&#xD;
             cardiovascular, gastrointestinal, musculoskeletal disease&#xD;
&#xD;
          -  Pregnant(positive urine HCG) or breastfeeding women if female&#xD;
&#xD;
          -  Subjects with a hereditary problems, for example, galactose intolerance, Lapp lactase&#xD;
             deficiency or glucose-galactose malabsorption&#xD;
&#xD;
          -  Subjects with a presence and a history of surgery or gastrointestinal diseases which&#xD;
             might significantly change absorption of medicines&#xD;
&#xD;
          -  Subjects with hypersensitivity or a history of clinically significant hyper&#xD;
             sensitivity to ingredients with IPs, excipients, other drugs including sulfonamide and&#xD;
             renin-angiotensin class&#xD;
&#xD;
          -  Subjects with the following results in clinical laboratory tests&#xD;
&#xD;
               -  AST/ALT/ALP/γ-GTP/Bilirubin total &gt; UNL (upper normal limit) × 2&#xD;
&#xD;
               -  Creatinine in plasma which is outside the accepted normal range or eGFR&#xD;
                  calculated by MDRD &lt; 60 mL/min/1.73 ㎡&#xD;
&#xD;
               -  CK &gt; UNL × 2&#xD;
&#xD;
          -  Subjects with a history of drug abuse or positive to drug abuse at urine drug&#xD;
             screening test&#xD;
&#xD;
          -  Subjects with systolic blood pressure (SBP) ≥ 140 mmHg or ≤ 90 mmHg, diastolic blood&#xD;
             pressure (DBP) ≥ 100 mmHg or ≤ 60 mmHg, or pulse rate (PR) ≤ 40 bpm or ≥ 100 bpm on&#xD;
             vital signs measured in sitting position after taking a rest for at least 3 minutes&#xD;
             during screening test&#xD;
&#xD;
          -  Subjects with clinically significant opinions including the following results in&#xD;
             12-lead ECG test during screening test&#xD;
&#xD;
               -  QTc &gt; 450 ms&#xD;
&#xD;
               -  PR interval &gt; 200 ms&#xD;
&#xD;
               -  QRS duration &gt; 120 ms&#xD;
&#xD;
          -  Subjects who have an abnormal diet that can affect ADME of drugs or consume foods that&#xD;
             can affect drug metabolism&#xD;
&#xD;
          -  Subjects who have taken any prescription drugs or herbal medicine within 2 weeks prior&#xD;
             to the 1st IP administration, or any over-the-counter (OTC) drug, health functional&#xD;
             food or vitamin preparation within 10 days to the 1st IP administration (However, can&#xD;
             participate in the study if otherwise eligible in the judgment of the investigator)&#xD;
&#xD;
          -  Subjects who have taken the drug which can induce or inhibit drug metabolism enzyme&#xD;
             within 1 month prior to the 1st IP administration&#xD;
&#xD;
          -  Subjects who have participated in any other clinical study or bioequivalnece study&#xD;
             within 6 months prior to the 1st IP administration(However, the criterion for&#xD;
             termination of participation in other clinical study or bioequivalence study is the&#xD;
             last administration date, and the next day is counted as one day.)&#xD;
&#xD;
          -  Subjects who have donated whole blood within 2 months prior to the 1st IP&#xD;
             administration or have donated blood components or received transfusion within 1 month&#xD;
             prior to the 1st IP administration&#xD;
&#xD;
          -  Subject who have continued drink of alcohol (&gt; 21 units/week, 1 unit = 10 g = 12.5 mL&#xD;
             of pure alcohol) within 6 months prior to the 1st IP administration or are unable to&#xD;
             stop drinking from the time of signing the informed consent form to post study visit&#xD;
&#xD;
               -  alcohol (g) = intake volume(mL) × level(%) × 0.8&#xD;
&#xD;
          -  Subject who have a history of excessive smoking (&gt; 10 cigarettes/day) within 3 months&#xD;
             prior to the 1st IP administration and unable to stop smoking from 24 hours before the&#xD;
             administration at each period to the last sampling time at each period&#xD;
&#xD;
          -  Subjects who take or are unable to stop foods containing grapefruit from 48 hours&#xD;
             before the 1st IP administration to post study visit&#xD;
&#xD;
          -  Subject who take or are unable to stop foods containing caffeine(coffee, green tea,&#xD;
             black tee, soda, coffee-flavored milk, nutritive tonic drink) from 24 hours before the&#xD;
             administration at each period to the last sampling time at each period&#xD;
&#xD;
          -  Subjects who have exercised vigorously exceeding the level of daily life during the&#xD;
             period from 48 hours before the 1st administration to post study visit, or who are&#xD;
             unable to stop vigorous exercise&#xD;
&#xD;
          -  Subjects or their spouse or partner who are not using an approved method of&#xD;
             contraception or even if are not planning to become pregnant (e.g., contraceptive&#xD;
             administration and implantation, intrauterine device, Those who are not using&#xD;
             procedures (vasectomy, tubal ligation, etc.) from the time of written consent of the&#xD;
             subject until two weeks after the last bioequivalence study drug administration date&#xD;
&#xD;
          -  Subjects who have determined that the investigator is unsuitable to participate in the&#xD;
             bioequivalence test due to reasons other than the above selection/exclusion criteria&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Heechan Lee, MS</last_name>
    <phone>+82-2-6477-0222</phone>
    <email>heechan.lee@inno-n.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chungbuk National University Hospital</name>
      <address>
        <city>Cheongju-si</city>
        <state>Chungcheongbuk-do</state>
        <zip>28644</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Min Kyu Park, MD, PhD</last_name>
      <phone>+82-43-269-8708</phone>
      <email>mk_park@cbnuhctc.com</email>
    </contact>
    <investigator>
      <last_name>Min Kyu Park, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 25, 2021</study_first_submitted>
  <study_first_submitted_qc>September 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 10, 2021</study_first_posted>
  <last_update_submitted>September 1, 2021</last_update_submitted>
  <last_update_submitted_qc>September 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Telmisartan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

